GlassScriptPhysician profile
Michael Hawthorne
NPI 1235159252
$1,993.35
in general payments reported to CMS, 2019-2025
22 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $28.61 · 2021: $26.03 · 2022: $49.61 · 2023: $339 · 2024: $335 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $639.74 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $553.47 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.64 | 2023-2025 | Dupixent |
| Baxter Healthcare | $136.45 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $72.74 | 2019-2023 | |
| Pfizer INC. | $59.28 | 2019 | |
| Insmed, INC. | $42.47 | 2025 | Brinsupri, Arikayce |
| Genentech USA, INC. | $41.98 | 2019-2022 | |
| Novo Nordisk INC | $36.26 | 2019-2025 | Ozempic |
| Pinnacle Biologics, INC | $32.26 | 2025 | Photofrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2024 | Ofev |
| Otsuka America Pharmaceutical, INC. | $26.27 | 2025 | Jynarque |
| Verona Pharma, INC. | $24.18 | 2025 | Ohtuvayre |
| Amgen INC. | $23.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.20 | 2025 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.72 | 2024 | Ryaltris |
| Philips North America LLC | $19.68 | 2025 | Vest Therapy Und |
| Viatris Specialty LLC | $19.55 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $18.22 | 2024 | Eliquis |
| Inspire Medical Systems, INC. | $15.62 | 2023 | Inspire |
| Shield Therapeutics INC | $14.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.72 | 2025 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hawthorne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.